Scott is an Entrepreneur-in-Residence on the Frazier Life Sciences team and has over 25 years of experience in the pharmaceutical industry.
Scott joined the Frazier Life Sciences team as an Entrepreneur-in-Residence in May 2020. He currently serves as the Chairman of the Board of Acacia Pharma Group plc. Previously, he was Chief Executive Officer at Outpost Medicine, a Frazier portfolio company.
Prior to Outpost, Scott was President and Chief Operating Officer of Acacia Pharma, Inc. From 2009 until its acquisition by Mallinckrodt Pharmaceuticals for $1.4 billion in 2014, he was Senior Vice President and Chief Commercial Officer of Cadence Pharmaceuticals. At Cadence, Scott built the company’s commercial and supply-chain infrastructure and led the launch of OFIRMEV, a market-leading non-opioid injectable analgesic. Earlier in his career, Scott served in a variety of roles of increasing responsibility at Eli Lilly and Company, including sales, marketing, development, manufacturing, and strategic planning.
Scott holds a B.S. in mechanical engineering from Bradley University and an M.B.A. from Harvard Business School.
Bradley University (B.S.)
Harvard Business School (M.B.A.)